The therapy of systemic lupus erythematosus (SLE), a systemic autoimmune disease of unknown aetiology, is significantly complicated by the diversity of disease manifestations and by a variety of complex immune abnormalities. Recent preclinical studies have shown the therapeutic efficacy of several. drugs and/or new compounds, some of which have been tested in clinical trials. This review provides an update on the use of new approaches in SLE and recent patents that could develop into novel therapeutics available to the clinical armamentarium for the management of the disease. © 2008 Bentham Science Publishers Ltd.
New therapies in SLE / Ferrera, F.; Filaci, G.; Rizzi, M.; Singh, R. P.; Indiveri, F.; Hahn, B. H.; La Cava, A.. - In: RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY. - ISSN 1872-213X. - 2:1(2008), pp. 11-23. [10.2174/187221308783399243]
New therapies in SLE
La Cava A.
2008
Abstract
The therapy of systemic lupus erythematosus (SLE), a systemic autoimmune disease of unknown aetiology, is significantly complicated by the diversity of disease manifestations and by a variety of complex immune abnormalities. Recent preclinical studies have shown the therapeutic efficacy of several. drugs and/or new compounds, some of which have been tested in clinical trials. This review provides an update on the use of new approaches in SLE and recent patents that could develop into novel therapeutics available to the clinical armamentarium for the management of the disease. © 2008 Bentham Science Publishers Ltd.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
